Vivoryon (VVY) Breakfast & Networking Event at AAIC 2022

San Diego, CA, August 2, 2022

Please join us and your fellow researchers, clinicians, and members of the investor community for Vivoryon’s AAIC 2022 Breakfast and Networking Event on Tuesday, August 2, 2022 at 7:15 a.m.!

This in-person and webcasted event will discuss the future of AD treatments and updates on our active Phase 2 VIVA-MIND and VIVIAD trials for varoglutamastat. The event also features spotlight presentations by the following:

 Prof. Howard Feldman, M.D., Professor of Neurosciences and Director of the ADCS at UC San Diego and VIVA-MIND study director
Cynthia Lemere, Ph.D., Associate Professor of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston.
Dr. Frank Weber, CMO, Vivoryon Therapeutics N.V., Halle/Saale & Munich, Germany

Please register via RSVP button or to Michael at and see below for more details:

Time: 7:15 a.m. - 8:15 a.m. PT (Registration and Breakfast begins at 6:45 a.m. PT)
Webcast will be available at this link or under the ‘News & Events’ Section of the Vivoryon website

6:45 a.m. - Arrival, Networking, Breakfast
7:15 a.m. - Welcome Remarks

7:20 a.m. - Spotlight Presentations
8:00 a.m. - Discussion and Networking 
8:15 a.m. - Closing

RSVP for Event / Log Back in Presenter Access

Additional menu options can be found in the menu bar on the left or at the top.

Vivoryon [VVY:AS] €367 MM MCap
De­vel­ops small molecule medicines that mo­d­u­late the ac­tiv­i­ty and sta­bil­i­ty of patho­log­i­cal­ly al­tered pro­teins. Lead can­di­date varog­lu­tam­s­tat, cur­rent­ly in VIVI­AD EU Ph2b and VI­VA-MIND US Ph2a/2b studies in Alzheimer’s dis­ease (AD), tar­gets all three ma­jor hall­marks of AD (Abe­ta pathol­o­gy, tau pathol­o­gy, neu­roin­flam­ma­tion) and sy­nap­tic im­pair­ment. [more in­for­ma­tion]